Patents by Inventor Glenn Huang
Glenn Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240087714Abstract: An exercise machine with a more natural gait and computer gaming interface which, in some embodiments, further allows for a variable stride length while in use. In one configuration, each side of the exercise machine has a first crank assembly connected at an upper location on a pedal arm and a second crank connected at a middle location on the pedal arm, and a pedal is attached to a lower location of the pedal arm. The first crank assembly is connected to the pedal arm by a crank arm. The second crank assembly is connected to the pedal arm via a crank arm pivotally attached to a crank link. The path of each pedal is determined by the lengths of crank arms and crank links of the first and second crank assemblies rotating in synchronous motion.Type: ApplicationFiled: November 20, 2023Publication date: March 14, 2024Inventors: Charles Huang, Christopher A. Larkin, Steven S.L. Toh, Koley C. Porter, Glenn F. Maynard, Coleman F. Fung
-
Patent number: 8609144Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.Type: GrantFiled: June 19, 2008Date of Patent: December 17, 2013Assignee: Allergan, Inc.Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton C. Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
-
Patent number: 8293741Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.Type: GrantFiled: April 29, 2005Date of Patent: October 23, 2012Assignee: Allergan, Inc.Inventors: James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany A. Jackson, Larry A. Wheeler, Rosy S. Donn
-
Publication number: 20080299178Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.Type: ApplicationFiled: June 19, 2008Publication date: December 4, 2008Applicant: ALLERGAN, INC.Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
-
Publication number: 20080260832Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.Type: ApplicationFiled: June 19, 2008Publication date: October 23, 2008Applicant: ALLERGAN, INC.Inventors: James Burke, Patrick M. Hughes, Orilla C. Werhner, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry A. Wheeler, Rosy S. Donn
-
Publication number: 20080118548Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.Type: ApplicationFiled: January 31, 2008Publication date: May 22, 2008Applicant: ALLERGAN, INC.Inventors: Glenn HUANG, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
-
Publication number: 20080118547Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.Type: ApplicationFiled: January 31, 2008Publication date: May 22, 2008Applicant: ALLERGAN, INC.Inventors: Glenn Huang, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
-
Publication number: 20080118549Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.Type: ApplicationFiled: January 31, 2008Publication date: May 22, 2008Applicant: ALLERGAN, INC.Inventors: Glenn HUANG, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
-
Publication number: 20070031472Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.Type: ApplicationFiled: June 23, 2006Publication date: February 8, 2007Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang, Orest Olejnik
-
Publication number: 20050271705Abstract: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.Type: ApplicationFiled: April 29, 2005Publication date: December 8, 2005Applicant: Allergan, Inc.Inventors: Patrick Hughes, Orest Olejnik, Glenn Huang, Joan-En Chang-Lin, Thierry Nivaggioli, JaneGuo Shiah, Michele Boix, Christian Sarrazin
-
Publication number: 20050244479Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.Type: ApplicationFiled: April 30, 2004Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, James Burke, Patrick Hughes, Kai-Ming Zhang, Ton Lin, Larry Wheeler, Rosy Donn
-
Publication number: 20050244506Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: ALLERGAN, INC.Inventors: James Burke, Patrick Hughes, Werhner Orilla, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry Wheeler, Rosy Donn
-
Publication number: 20050244468Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: ApplicationFiled: April 30, 2004Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli
-
Publication number: 20050244474Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang, Orest Olejnik
-
Publication number: 20050244476Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: ALLERGAN, INC.Inventors: James Burke, Patrick Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany Jackson, Larry Wheeler, Rosy Donn
-
Publication number: 20050244458Abstract: Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.Type: ApplicationFiled: April 30, 2004Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli
-
Publication number: 20050244463Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.Type: ApplicationFiled: April 30, 2004Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn